AVENUE THERAPEUTICS, INC. (ATXI)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Avenue Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | 0.2800 | 0.2800 | 0.2800 | 0.2800 | 2,828 |
| Nov 9, 2026 | 0.2800 | 0.4289 | 0.2800 | 0.3053 | 1,129 |
| Nov 5, 2026 | 0.4289 | 0.4289 | 0.4289 | 0.4289 | 117 |
| Nov 2, 2026 | 0.4019 | 0.4019 | 0.4019 | 0.4019 | 2,097 |
| Oct 30, 2026 | 0.4279 | 0.4279 | 0.4279 | 0.4279 | 301 |
| Oct 28, 2026 | 0.3800 | 0.3800 | 0.3800 | 0.3800 | 5,007 |
| Oct 27, 2026 | 0.4170 | 0.4170 | 0.3985 | 0.3985 | 2,115 |
| Oct 26, 2026 | 0.4018 | 0.4123 | 0.4000 | 0.4123 | 13,998 |
| Oct 23, 2026 | 0.3850 | 0.3850 | 0.3850 | 0.3850 | 234 |
| Oct 20, 2026 | 0.4042 | 0.4042 | 0.4042 | 0.4042 | 104 |
| Oct 14, 2026 | 0.4300 | 0.4300 | 0.4300 | 0.4300 | 329 |
| Oct 13, 2026 | 0.4403 | 0.4403 | 0.4200 | 0.4200 | 3,036 |
| Oct 12, 2026 | 0.4490 | 0.4490 | 0.4005 | 0.4005 | 488 |
| Oct 8, 2026 | 0.4298 | 0.4298 | 0.4298 | 0.4298 | 249 |
| Oct 7, 2026 | 0.3816 | 0.4490 | 0.3816 | 0.4490 | 6,121 |
| Oct 5, 2026 | 0.3800 | 0.3800 | 0.3800 | 0.3800 | 604 |
| Oct 2, 2026 | 0.4076 | 0.4076 | 0.4076 | 0.4076 | 1,083 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| 10% Owner | Grant/Award | 111.2K | -- | Jan 2, 2026 | |
| 10% Owner | Grant/Award | 33.7K | -- | Mar 31, 2025 | |
| Director | Sale | 23 | $46 | Dec 2, 2024 | |
| Director | Sale | 61 | $136.64 | Nov 5, 2024 | |
| Director | Purchase | 497 | $1.2K | Sep 30, 2024 | |
| Director | Purchase | 3 | $7.2 | Sep 27, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
Fortress Biotech, Inc. · may incl. warrants· filed Jan 2026 | 440.0K | 13.4% | 13D |
MacLean Alexandra Chief Executive Officer, Director | 170.0K | 5.2% | FORM 4 |
Ikarian Capital, LLC · may incl. warrants· filed Feb 2026 | 130.8K | 4.0% | 13G |
Armistice Capital, LLC · may incl. warrants· filed Feb 2025 | 100.4K | 3.0% | 13G |
Jin David Interim PFO and COO | 65.0K | 2.0% | FORM 4 |
Robert Davidow · may incl. warrants· stale · filed May 2024 | 17.2K | 0.5% | 13G |
Sabby Volatility Warrant Master Fund, Ltd. · filed Jan 2024 | 8.8K | 0.3% | 13G |
KRANZLER JAY D Director | 559 | 0.0% | FORM 4 |
Herskowitz Neil Director | 97 | 0.0% | FORM 4 |
Insiders
- Fortress Biotech, Inc.10% Owner
- Herskowitz NeilDirector
- KRANZLER JAY DDirector
- MacLean AlexandraChief Executive Officer
- Charles Faith L.Director
- Jin DavidInterim PFO and COO
- ROSENWALD LINDSAY A MDDirector
- Oltmans Curtis GaleDirector
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
2.79K
60d Avg
4.37K
90d Avg
9.03K
Signal8's dilution snapshot of ATXI as of Sep 30, 2026 records 3 outstanding warrant series, from SEC filings. Avenue Therapeutics, Inc. (OTC: ATXI) traded at $0.2800 on Nov 12, 2026, down 8.29% from the previous close of $0.3053. 52-week range: $0.1500 to $0.9570. The company is in the Healthcare sector (Biotechnology).